Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
Introduction: HER-2/neu status determines the eligibility for targeted therapy with trastuzumab in breast carcinoma. Evaluation for HER-2/neu protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) has become the gold standard. Aims: Since...
Saved in:
Main Authors: | Sudha S Murthy (Author), D G Sandhya (Author), Faiq Ahmed (Author), K Iravathy Goud (Author), Monal Dayal (Author), K Suseela (Author), Senthil J Rajappa (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2011-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables
by: Zaidoon A. Musa, et al.
Published: (2017) -
HTLV 1 associated adult T cell lymphoma/leukemia a clinicopathologic, immunophenotypic tale of three cases from non-endemic region of south India
by: Faiq Ahmed, et al.
Published: (2012) -
Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry
by: Ibrahim Al Haddabi, et al.
Published: (2014) -
Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
by: Xiao-Ying Zhang, et al.
Published: (2023) -
Correlation and comparison of immunohistochemistry for HER2/neu, using the antibody SP3 and chromogenic in situ hybridization in breast carcinomas samples
by: Franciele F. Wolf, et al.
Published: (2015)